

# **EXHIBIT C**

Display Settings: Summary, 20 per page, Sorted by Recently Added

Results: 1 to 20 of 58

1. [Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study.](#)  
Mueller S, Polley MY, Lee B, Kunwar S, Pedain C, Wembacher-Schröder E, Mittermeyer S, Westphal M, Sampson JH, Vogelbaum MA, Croteau D, Chang SM.  
J Neurooncol. 2010 Jun 20. [Epub ahead of print]  
PMID: 20563833 [PubMed - as supplied by publisher]
2. [Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.](#)  
Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK; PRECISE Study Group.  
Neuro Oncol. 2010 Feb 4. [Epub ahead of print]  
PMID: 20511192 [PubMed - as supplied by publisher]
3. [Therapeutic efficacy of Cintredekin Besudotox \(IL13-PE38QQR\) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A.](#)  
Rosada RS, Moreira AP, Frantz FG, Puri RK, Rahman A, Standiford TJ, Zárate-Bladés CR, Silva CL, Hogaboam CM.  
PLoS One. 2010 Jan 15;5(1):e8721.  
PMID: 20090941 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#)
4. [CONVECTION-ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX \(INTERLEUKIN-13-PE38QQR\) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT GLIOMAS: PHASE 1 STUDY OF FINAL SAFETY RESULTS.](#)  
Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK.  
Neurosurgery. 2008 Sep 15. [Epub ahead of print]  
PMID: 18827726 [PubMed - as supplied by publisher]
5. [Cintredekin besudotox in treatment of malignant glioma.](#)  
Mut M, Sherman JH, Shaffrey ME, Schiff D.  
Expert Opin Biol Ther. 2008 Jun;8(6):805-12. Review.  
PMID: 18476792 [PubMed - indexed for MEDLINE]
6. [Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy.](#)  
Wykosky J, Gibo DM, Stanton C, Debinski W.  
Clin Cancer Res. 2008 Jan 1;14(1):199-208.  
PMID: 18172271 [PubMed - indexed for MEDLINE] [Free Article](#)
7. [Crossing borders: surgically mediated drug delivery techniques.](#)  
Asthagiri AR, Baggenstos M, Lonser RR.  
Clin Neurosurg. 2008;55:27-34. Review. No abstract available.  
PMID: 19248666 [PubMed - indexed for MEDLINE]
8. [Convection-enhanced delivery of cintredekin besudotox \(interleukin-13-PE38QQR\) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.](#)  
Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK.  
Neurosurgery. 2007 Nov;61(5):1031-7; discussion 1037-8.  
PMID: 18091279 [PubMed - indexed for MEDLINE]
9. [A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells.](#)  
Wykosky J, Gibo DM, Debinski W.  
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3208-18.  
PMID: 18089715 [PubMed - indexed for MEDLINE] [Free Article](#)
10. [Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies.](#)  
Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK.  
Cancer Res. 2007 Sep 1;67(17):7983-6.  
PMID: 17804706 [PubMed - indexed for MEDLINE] [Free Article](#)
11. [Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors.](#)  
Ferguson S, Lesniak MS.  
Curr Drug Deliv. 2007 Apr;4(2):169-80. Review.  
PMID: 17456036 [PubMed - indexed for MEDLINE]

12. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.  
 Sampson JH, Raghavan R, Brady ML, Provenzale JM, Herndon JE 2nd, Croteau D, Friedman AH, Reardon DA, Coleman RE, Wong T, Bigner DD, Pastan I, Rodríguez-Ponce MI, Tanner P, Puri R, Pedain C.  
 Neuro Oncol. 2007 Jul;9(3):343-53. Epub 2007 Apr 13.  
 PMID: 17435179 [PubMed - indexed for MEDLINE]    [Free PMC Article](#)    [Free text](#)
  
13. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.  
 Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK; Cintredekin Besudotox Intraparenchymal Study Group.  
 J Clin Oncol. 2007 Mar 1;25(7):837-44.  
 PMID: 17327604 [PubMed - indexed for MEDLINE]
  
14. Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin.  
 Sampson JH, Raghavan R, Provenzale JM, Croteau D, Reardon DA, Coleman RE, Rodríguez Ponce I, Pastan I, Puri RK, Pedain C.  
 AJR Am J Roentgenol. 2007 Mar;188(3):703-9.  
 PMID: 17312057 [PubMed - indexed for MEDLINE]    [Free Article](#)
  
15. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning.  
 Sampson JH, Brady ML, Petry NA, Croteau D, Friedman AH, Friedman HS, Wong T, Bigner DD, Pastan I, Puri RK, Pedain C.  
 Neurosurgery. 2007 Feb;60(2 Suppl 1):ONS89-98; discussion ONS98-9.  
 PMID: 17297371 [PubMed - indexed for MEDLINE]
  
16. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties.  
 Kawakami K, Nakajima O, Morishita R, Nagai R.  
 ScientificWorldJournal. 2006 Jul 7;6:781-90. Review.  
 PMID: 16830050 [PubMed - indexed for MEDLINE]
  
17. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.  
 Kunwar S, Chang SM, Prados MD, Berger MS, Sampson JH, Croteau D, Sherman JW, Grahm AY, Shu VS, Dul JL, Husain SR, Joshi BH, Pedain C, Puri RK.  
 Neurosurg Focus. 2006 Apr 15;20(4):E15.  
 PMID: 16709020 [PubMed - indexed for MEDLINE]
  
18. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.  
 Shimamura T, Husain SR, Puri RK.  
 Neurosurg Focus. 2006 Apr 15;20(4):E11. Review.  
 PMID: 16709016 [PubMed - indexed for MEDLINE]
  
19. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.  
 Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK.  
 Technol Cancer Res Treat. 2006 Jun;5(3):239-50. Review.  
 PMID: 16700620 [PubMed - indexed for MEDLINE]
  
20. Convection-enhanced and local delivery of targeted cytotoxins in the treatment of malignant gliomas.  
 Muro K, Das S, Raizer JJ.  
 Technol Cancer Res Treat. 2006 Jun;5(3):201-13. Review.  
 PMID: 16700617 [PubMed - indexed for MEDLINE]

Display Settings: Summary, 20 per page, Sorted by Recently Added

Results: 21 to 40 of 86

21. [Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model.](#)  
Kawakami M, Kawakami K, Kioi M, Leland P, Puri RK.  
Blood. 2005 May 1;105(9):3707-13. Epub 2004 Dec 30.  
PMID: 15626735 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#)
22. [Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.](#)  
Beseth BD, Cameron RB, Leland P, You L, Varricchio F, Kreitman RJ, Maki RA, Jablons DM, Husain SR, Puri RK.  
Ann Thorac Surg. 2004 Aug;78(2):436-43; discussion 436-43.  
PMID: 15276492 [PubMed - indexed for MEDLINE]
23. [Gateways to clinical trials.](#)  
Bayés M, Rabasseda X, Prous JR.  
Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44.  
PMID: 15148527 [PubMed - indexed for MEDLINE]
24. [Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.](#)  
Kawakami M, Kawakami K, Puri RK.  
J Neurooncol. 2003 Oct;65(1):15-25. Review.  
PMID: 14649882 [PubMed - indexed for MEDLINE]
25. [Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1.](#)  
de Jong MC, Scheffer GL, Broxterman HJ, Hooijberg JH, Slootstra JW, Meloen RH, Kreitman RJ, Husain SR, Joshi BH, Puri RK, Scheper RJ.  
Clin Cancer Res. 2003 Oct 15;9(13):5009-17.  
PMID: 14581376 [PubMed - indexed for MEDLINE] [Free Article](#)
26. [IL-4 receptor-directed cytotoxin for therapy of AIDS-associated KS tumors.](#)  
Puri RK.  
Drug News Perspect. 2000 Sep;13(7):395-402.  
PMID: 12937611 [PubMed]
27. [Immunobiological treatments of hairy-cell leukaemia.](#)  
Kreitman RJ, Pastan I.  
Best Pract Res Clin Haematol. 2003 Mar;16(1):117-33. Review.  
PMID: 12670470 [PubMed - indexed for MEDLINE]
28. [Interleukin-4 receptor-targeted cytotoxin therapy of androgen-dependent and -independent prostate carcinoma in xenograft models.](#)  
Husain SR, Kawakami K, Kawakami M, Puri RK.  
Mol Cancer Ther. 2003 Mar;2(3):245-54.  
PMID: 12657719 [PubMed - indexed for MEDLINE] [Free Article](#)
29. [\[Synergistic cytotoxic effect of immunotoxin HEL-PE38KDEL and cis-platin against tumor cells\]](#)  
Wang JS, Wang SM, Chen GR, Yang DJ.  
Ai Zheng. 2002 Apr;21(4):360-3. Chinese.  
PMID: 12452011 [PubMed - indexed for MEDLINE]
30. [Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.](#)  
Kawakami M, Kawakami K, Stephens VA, Maki RA, Robin H, Muller W, Husain SR, Puri RK.  
Clin Cancer Res. 2002 Nov;8(11):3503-11.  
PMID: 12429641 [PubMed - indexed for MEDLINE] [Free Article](#)
31. [IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein.](#)  
Joshi BH, Leland P, Silber J, Kreitman RJ, Pastan I, Berger M, Puri RK.  
Br J Cancer. 2002 Jan 21;86(2):285-91.  
PMID: 11870521 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#)
32. [Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.](#)  
Decker T, Hipp S, Kreitman RJ, Pastan I, Peschel C, Licht T.  
Blood. 2002 Feb 15;99(4):1320-6.  
PMID: 11830482 [PubMed - indexed for MEDLINE] [Free Article](#)
33. [Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.](#)

Strome SE, Kawakami K, Alejandro D, Voss S, Kasperbauer JL, Salomao D, Chen L, Maki RA, Puri RK.  
Clin Cancer Res. 2002 Jan;8(1):281-6.  
PMID: 11801570 [PubMed - indexed for MEDLINE] Free Article

34. Internalization property of interleukin-4 receptor alpha chain increases cytotoxic effect of interleukin-4 receptor-targeted cytotoxin in cancer cells.  
Kawakami K, Kawakami M, Leland P, Puri RK.  
Clin Cancer Res. 2002 Jan;8(1):258-66.  
PMID: 11801567 [PubMed - indexed for MEDLINE] Free Article
35. Biologic therapy for psoriasis: a brief history, I.  
Tutrone WD, Kagen MH, Barbagallo J, Weinberg JM.  
Cutis. 2001 Nov;68(5):331-6. Review.  
PMID: 11766118 [PubMed - indexed for MEDLINE]
36. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.  
Joshi BH, Leland P, Asher A, Prayson RA, Varricchio F, Puri RK.  
Cancer Res. 2001 Nov 15;61(22):8058-61.  
PMID: 11719427 [PubMed - indexed for MEDLINE] Free Article
37. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy.  
Kawakami K, Kawakami M, Puri RK.  
Crit Rev Immunol. 2001;21(1-3):299-310. Review.  
PMID: 11642612 [PubMed - indexed for MEDLINE]
38. Cytotoxins directed at interleukin-4 receptors as therapy for human brain tumors.  
Puri RK.  
Methods Mol Biol. 2001;166:155-76. Review. No abstract available.  
PMID: 11217365 [PubMed - indexed for MEDLINE]
39. Quantification of immunotoxin number for complete therapeutic response.  
Kreitman RJ.  
Methods Mol Biol. 2001;166:111-23. Review. No abstract available.  
PMID: 11217362 [PubMed - indexed for MEDLINE]
40. Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2.  
Onda M, Willingham M, Wang QC, Kreitman RJ, Tsutsumi Y, Nagata S, Pastan I.  
J Immunol. 2000 Dec 15;165(12):7150-6.  
PMID: 11120846 [PubMed - indexed for MEDLINE] Free Article

Display Settings: Summary, 20 per page, Sorted by Recently Added

## Results: 41 to 58 of 58

41. Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist.  
Oshima Y, Puri RK.  
Cell Immunol. 2001 Jul 10;211(1):37-42.  
PMID: 11585386 [PubMed - indexed for MEDLINE]
42. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.  
Kawakami K, Kawakami M, Joshi BH, Puri RK.  
Cancer Res. 2001 Aug 15;61(16):6194-200.  
PMID: 11507072 [PubMed - indexed for MEDLINE] Free Article
43. Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain.  
Kawakami K, Takeshita F, Puri RK.  
J Biol Chem. 2001 Jul 6;276(27):25114-20. Epub 2001 May 14.  
PMID: 11352909 [PubMed - indexed for MEDLINE]
44. The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway.  
Kawakami K, Taguchi J, Murata T, Puri RK.  
Blood. 2001 May 1;97(9):2673-9.  
PMID: 11313257 [PubMed - indexed for MEDLINE] Free Article
45. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.  
Husain SR, Joshi BH, Puri RK.  
Int J Cancer. 2001 Apr 15;92(2):168-75.  
PMID: 11291041 [PubMed - indexed for MEDLINE]
46. Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain.  
Kawakami K, Joshi BH, Puri RK.  
Hum Gene Ther. 2000 Sep 1;11(13):1829-35.  
PMID: 10986556 [PubMed - indexed for MEDLINE]
47. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft.  
Husain SR, Puri RK.  
Blood. 2000 Jun 1;95(11):3506-13.  
PMID: 10828036 [PubMed - indexed for MEDLINE] Free Article
48. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4.  
Kornmann M, Kleeff J, Debinski W, Korc M.  
Anticancer Res. 1999 Jan-Feb;19(1A):125-31.  
PMID: 10226533 [PubMed - indexed for MEDLINE]
49. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin.  
Maini A, Hillman G, Haas GP, Wang CY, Montecillo E, Hamzavi F, Pontes JE, Leland P, Pastan I, Debinski W, Puri RK.  
J Urol. 1997 Sep;158(3 Pt 1):948-53.  
PMID: 9258124 [PubMed - indexed for MEDLINE]
50. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein.  
Husain SR, Obiri NI, Gill P, Zheng T, Pastan I, Debinski W, Puri RK.  
Clin Cancer Res. 1997 Feb;3(2):151-6.  
PMID: 9815666 [PubMed - indexed for MEDLINE] Free Article
51. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells.  
Debinski W, Miner R, Leland P, Obiri NI, Puri RK.  
J Biol Chem. 1996 Sep 13;271(37):22428-33.  
PMID: 8798406 [PubMed - indexed for MEDLINE] Free Article
52. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).  
Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP, Pastan I, Debinski W.

Blood. 1996 May 15;87(10):4333-9.

PMID: 8639793 [PubMed - indexed for MEDLINE] Free Article

53. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin.  
Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK.  
Clin Cancer Res. 1995 Nov;1(11):1253-8.  
PMID: 9815919 [PubMed - indexed for MEDLINE] Free Article
54. Recombinant F(ab') C242-Pseudomonas exotoxin, but not the whole antibody-based immunotoxin, causes regression of a human colorectal tumor xenograft.  
Debinski W, Pastan I.  
Clin Cancer Res. 1995 Sep;1(9):1015-22.  
PMID: 9816074 [PubMed - indexed for MEDLINE] Free Article
55. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4.  
Debinski W, Obiri NI, Pastan I, Puri RK.  
J Biol Chem. 1995 Jul 14;270(28):16775-80.  
PMID: 7622490 [PubMed - indexed for MEDLINE] Free Article
56. Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin.  
Debinski W, Puri RK, Pastan I.  
Int J Cancer. 1994 Sep 1;58(5):744-8.  
PMID: 8077061 [PubMed - indexed for MEDLINE]
57. An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin.  
Debinski W, Pastan I.  
Bioconjug Chem. 1994 Jan-Feb;5(1):40-6.  
PMID: 8199233 [PubMed - indexed for MEDLINE]
58. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.  
Debinski W, Pastan I.  
Cancer Res. 1992 Oct 1;52(19):5379-85.  
PMID: 1394141 [PubMed - indexed for MEDLINE] Free Article